|
KMID : 0816120100130010044
|
|
Korean Journal of Pediatric Gastroenterolology and Nutrition
2010 Volume.13 No. 1 p.44 ~ p.50
|
|
|
Experience with Entecavir Therapy for Lamivudine-Resistant Chronic Hepatitis B in Korean Children and Adolescents
|
|
Cho Seung-Man
Choe Byung-Ho
Kim Jung-mi
Chu Mi-Ae
|
|
|
Abstract
|
|
|
Purpose: To estimate the viral suppressive effect of entecavir monotherapy in Korean children and adolescents with lamivudine-resistant chronic hepatitis B (CHB).
Methods: One milligram of entecavir was administered once daily to 6 patients (4 boys; mean age, 17.5 years; range, 15.10∼24.6 years) with lamivudine-resistant CHB for a mean duration of therapy of 13.4 months (range, 1∼21.1 months). The therapeutic results were compared with 11 patients who received adefovir (0.3 mg/kg/day [maximal dose 10 mg]) for at least 12 months (mean, 33.4 months; range, 12.4∼58.3 months). The serum HBV DNA level and serologic markers were measured every 2 months.
Results: The interval to a HBV DNA titer decrement (＞1 log10) was 1.2±0.2 and 4.4±5.2 months (p=0.185) for the entecavir and adefovir groups, respectively. The interval to a HBV DNA titer decrement (＞2 log10) was 2.4±2.3 and 9.2±7.3 months (p=0.025), for the entecavir and adefovir groups, respectively.
Conclusion: The therapeutic efficacy of entecavir was favorable in children and adolescents, especially in shortening the interval to a ＞2 log10 decrement in the HBV DNA titer. Long-term follow up is needed to determine the therapeutic efficacy of entecavir for lamivudine-resistant CHB in children and adolescents.
|
|
|
KEYWORD
|
|
|
Entecavir, Adefovir, Lamivudine, Chronic hepatitis B, Resistance
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|